Body Pharm NAD+ 1000 Pen: Benefits, Use & Where to Buy

The Body Pharm NAD+ 1000 Pen is a prefilled subcutaneous auto-injector that delivers 1000 mg of nicotinamide adenine dinucleotide (NAD+) per pen. Injecting NAD+ places it into the bloodstream directly, sidestepping the gut, where oral NAD+ precursors such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are absorbed and metabolised to circulating NAD+ metabolites over several hours rather than raising NAD+ instantly. For South African adults exploring cellular energy, recovery, cognitive support or longevity protocols, the pen packages what has usually been a clinic-based intravenous (IV) approach into a self-administered format. It sells on Beskinny.store in 2026 for around R2,000 (from R2,200). Before you buy, it is worth understanding what NAD+ actually does, what the evidence does and does not show, and the pen’s regulatory status in South Africa.

In this article you will learn:

How the NAD+ 1000 Pen works and why buyers choose injection over oral precursors.
Who it may suit, how it is dosed and stored, and the risks and unknowns to weigh.
Where and how to buy the pen in South Africa, including legal status.

Key Takeaways

The pen delivers a 1000 mg NAD+ dose subcutaneously; batch HPLC assay reports 98.86% purity and a sterile, low-endotoxin solution.
NAD+ is a coenzyme that powers mitochondrial energy production, DNA repair and sirtuin signalling, and its levels decline with age in human tissue.
Human data are strongest for oral NAD+ precursors and IV NAD+; head-to-head pharmacokinetic data for a subcutaneous NAD+ pen are not established, so treat efficacy claims as early rather than proven.
Reported benefits include energy, focus and recovery support; documented risks are generally mild (flushing, warmth, injection-site reaction), with long-term human safety data still limited.
Store at 2–8 °C, in the dark, and never freeze. NAD+ is not a SAHPRA-registered medicine; it is sold as a research compound.

What Is the Body Pharm NAD+ 1000 Pen?

The Body Pharm NAD+ 1000 Pen is a prefilled auto-injector containing 1000 mg of NAD+ per 3 mL cartridge, manufactured by Body Pharm — a research-compound brand — for self-administered cellular-energy, recovery and longevity protocols. The accompanying certificate of analysis reports 98.86% purity, total impurities under 1.2%, a sterile solution and less than 1 EU/mg bacterial endotoxin for the tested batch, which is the kind of authenticity documentation worth checking before buying any injectable.

Some readers wonder whether a self-administered pen can match clinic-grade delivery. The prefilled format standardises the dose and sterility, but it does not turn an early-evidence research compound into a registered medicine — that distinction is covered in the regulatory section below.

Pen vs. Vial: Format Differences

The prefilled pen comes pre-measured, unlike a multi-dose NAD+ vial format that requires drawing into a separate syringe. Pre-measurement reduces dosing error and simplifies the 2–8 °C cold-chain handling that the product’s storage instructions require. The pen sits within Body Pharm’s broader wellness injections range alongside other research-grade compounds aimed at metabolic and recovery support.

Why NAD+ Levels Matter for Energy and Ageing

NAD+ matters because it is a coenzyme present in every cell. NAD+ powers adenosine triphosphate (ATP) synthesis in the mitochondria, supports DNA repair through poly-ADP-ribose polymerase (PARP) enzymes, and activates the sirtuins, a family of longevity-linked proteins. When NAD+ is insufficient, mitochondria produce less ATP, damaged DNA accumulates, and sirtuin-mediated stress resistance falters.

NAD+ also falls with age. Measurements in human tissue show that NAD+ concentrations decline substantially from youth into later adulthood, tracking with accumulating oxidative DNA damage and PARP activity. Chronic stress, poor sleep, illness, heavy alcohol intake and intense training can add to NAD+ consumption through repair pathways. This age-related decline is the rationale behind supplementing NAD+ via the NAD+ vial format or pens, and it is reviewed in the wider literature on NAD+ metabolism and its precursors in ageing.

Whether raising NAD+ carries long-term risks is a fair question. Short- and medium-term human studies of NAD+ precursors show good tolerability, but multi-year human safety data remain limited.

Injection vs. Oral NAD+: What the Evidence Shows

Buyers choose an injectable route because oral NAD+ precursors must survive digestion and first-pass metabolism before any NAD+ reaches the cells, whereas an injection enters the circulation directly. In a human study, single oral doses of 100–500 mg NMN were safe and raised NMN metabolites over roughly 5 hours, and parenteral delivery removes that absorption step. Human data confirm that giving NAD+ directly does raise circulating levels: in a pilot study, a 6-hour intravenous NAD+ infusion produced measurable rises in plasma and urinary NAD+ metabolites within hours.

An honest caveat matters here: those human data are for oral precursors and for IV infusion. We are not aware of published head-to-head pharmacokinetic studies comparing a subcutaneous NAD+ pen against oral or IV routes, so the exact plasma curve for this pen is an extrapolation rather than a measured value. IV infusion remains the clinical reference point but requires a clinic visit and 1–4 hours per session; the pen is positioned as an at-home alternative, not a proven equivalent. For format alternatives, see the NAD+ vial format or the broader wellness injections range.

Key Benefits of the NAD+ 1000 Pen

The benefits below follow from NAD+’s role as a coenzyme in cellular metabolism, DNA repair and neuronal signalling. Where a claim rests on precursor or IV data rather than on the subcutaneous pen specifically, we say so.

Cellular energy — NAD+ is a direct cofactor in mitochondrial ATP synthesis. This is established biochemistry; the subjective “energy” buyers report is individual and not a guaranteed outcome.
Focus and cognitive support — mechanistic. NAD+-dependent enzymes regulate neuronal redox balance and feature heavily in the literature on NAD+ in brain ageing. Reports of sharper focus after dosing are anecdotal, not from controlled trials.
Physical recovery — mechanistic. Sirtuin and PARP activity link NAD+ to DNA repair and stress resistance, but human recovery outcomes from a NAD+ pen are not established in trials.
DNA repair and longevity support — NAD+ fuels the PARP enzymes involved in repairing age-related DNA damage. Extrapolation to human lifespan is speculative.
Cardiometabolic markers — in a 28-day randomised trial, NAD augmentation raised circulating NAD+ and modestly lowered body weight, LDL cholesterol and diastolic blood pressure — but did not improve insulin sensitivity or muscle mitochondrial function. Treat NAD+ as a support tool, not a metabolic cure.
At-home convenience — a pre-measured 1000 mg dose self-delivered in seconds; compare with the NAD+ vial format.

Subjective effects like energy and focus vary between individuals, and not every user notices a change in the first week. Anyone presenting these as proven clinical outcomes is overstating the evidence.

Who Should Consider the NAD+ 1000 Pen?

The pen is aimed at health-conscious adults who are already researching NAD+ and want an at-home format rather than repeated clinic infusions, keeping in mind the age-related decline in cellular NAD+.

Typical Candidates

Biohackers and longevity enthusiasts already familiar with NMN or NR who prefer an injectable route.
Active adults and athletes using NAD+ as part of a recovery and metabolic-conditioning routine.
Executives and shift workers managing fatigue, on the understanding that the evidence for a cognitive-energy benefit is mechanistic rather than proven.
Adults exploring general convalescence and healthy-ageing protocols, an area of active NAD+ research rather than an approved treatment for any condition.

Anyone who is pregnant or breastfeeding, taking prescription medication (including chemotherapy or PARP inhibitors), or managing a chronic condition should speak to a clinician before starting, because interaction data for injectable NAD+ are limited.

How to Use the NAD+ 1000 Pen: Handling Guide

Administer the prefilled pen subcutaneously into the abdomen (avoiding a 5 cm radius around the navel) or the outer thigh. Clean the site with an alcohol swab, pinch a fold of skin, insert the needle, depress the pen fully, hold for 5–10 seconds for full delivery, then withdraw and apply gentle pressure. Rotate injection sites to reduce local irritation. This technique mirrors the auto-injector approach used across glucagon-like peptide-1 (GLP-1) and peptide pen protocols.

Timing and Cycling

Inject in the morning or early afternoon rather than late evening. NAD+ and its salvage enzyme NAMPT follow a daily rhythm — in mice, the circadian NAD+ cycle drives mitochondrial oxidative metabolism — so early dosing aligns with that peak. Community and practitioner protocols typically run a short loading phase before less-frequent maintenance dosing, but exact frequency and dose are not set by any registered protocol for this pen; confirm your schedule with a healthcare provider. Compare the NAD+ vial format or browse the wellness injections range for alternatives.

If self-injection feels intimidating, the auto-injector design hides the needle and standardises depth, which lowers the technical barrier compared with vial-and-syringe methods.

Storage, Handling, and Safety

Store the Body Pharm NAD+ 1000 Pen refrigerated at 2–8 °C, in a dark, sealed container, and never frozen, per the storage conditions on the accompanying BodyPharm certificate of analysis. NAD+ in solution is chemically labile, so keep the pen in its original packaging, protect it from light, and confirm in-use shelf life with the supplier documentation. A frozen pen should be discarded.

Safety and Tolerability

NAD+ is a naturally occurring coenzyme, and injected NAD+ is generally reported as well tolerated, with transient flushing, warmth or injection-site redness that usually settle quickly; a benefit/risk review of NAD+ therapy in age-related disorders reaches broadly the same conclusion while noting that robust long-term human safety data are still lacking. Consult a healthcare professional before starting if you take prescription medications, are pregnant, or manage a chronic condition.

The honest summary on safety: short- and medium-term tolerability looks good, but multi-year human safety trials for injectable NAD+ do not yet exist — a real point of uncertainty buyers should weigh.

Frequently Asked Questions

How quickly will I notice results from the NAD+ pen?

Some users report subjective energy or mental-clarity changes within a few days, but these reports are anecdotal. What is documented is that giving NAD+ parenterally raises circulating NAD+ metabolites within hours; measurable physiological changes in trials of NAD+ precursors accrued over weeks, not hours. Subcutaneous absorption is slower than IV, so any onset is gradual.

How does the pen compare to IV NAD+ infusions?

IV NAD+ delivers a faster plasma rise but requires a clinic visit of several hours and typically costs several thousand rand per session in South African clinics. The pen is positioned as a lower-cost, at-home alternative. Bear in mind there is no published head-to-head study proving the pen matches IV outcomes; the clinical NAD+ literature is still mostly built on IV and precursor data.

Can I stack NAD+ with other peptides?

Users commonly run NAD+ alongside peptide or GLP-1 protocols on the rationale that NAD+ acts on separate sirtuin and PARP pathways. Formal interaction data for these combinations are limited, so confirm any stack with your prescribing practitioner rather than assuming it is safe.

Is the NAD+ pen legal to buy in South Africa?

NAD+ is sold as a research compound and is not a SAHPRA-registered medicine. Injectable products in this category sit in a regulatory grey area; buyers should confirm the current scheduling and regulatory status with SAHPRA before purchase and involve a clinician.

How many pens do I need per month?

That depends entirely on the dose and frequency you and your clinician settle on, which is not fixed by any registered protocol for this pen. Confirm the pen’s per-dose delivery with the supplier so you can plan quantities accurately.

Where can I buy the pen in South Africa?

Order the Body Pharm NAD+ 1000 Pen directly from the wellness injections range, or choose the NAD+ vial format if you prefer a multi-dose presentation — both ship cold-chain across South Africa.

Next Step

If the pen fits your protocol, verify the current price and stock on Beskinny.store, confirm the pen’s per-dose delivery with the supplier, and consult your healthcare provider to design a schedule that fits your goals. NAD+ is an unregistered research compound in South Africa, so medical supervision matters — especially if you are combining it with other injectables.

References

NAD+ in Aging, Metabolism, and Neurodegeneration. Science (Verdin), 2015.
Age-Associated Changes in Oxidative Stress and NAD+ Metabolism in Human Tissue. PLOS ONE (Massudi et al.), 2012.
NAD+ in Brain Aging and Neurodegenerative Disorders. Cell Metabolism (Lautrup et al.), 2019.
Effect of Oral Administration of Nicotinamide Mononucleotide on Clinical Parameters and Nicotinamide Metabolite Levels in Healthy Japanese Men. Endocrine Journal (Irie et al.), 2020.
A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6-Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience (Grant et al.), 2019.
Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. Journal of Clinical Endocrinology & Metabolism (Pencina et al.), 2023.
Circadian Clock NAD+ Cycle Drives Mitochondrial Oxidative Metabolism in Mice. Science (Peek et al.), 2013.
NAD+ Therapy in Age-Related Degenerative Disorders: A Benefit/Risk Analysis. Experimental Gerontology (Braidy & Liu), 2020.
Scheduling of Substances (Complementary Medicines). South African Health Products Regulatory Authority (SAHPRA), 2024.
NAD+ 1000 Pen Certificate of Analysis (Batch NA18003 — purity, sterility and storage conditions). Body Pharm, 2025.